KNSA vs TFX: fair value comparison
Kiniksa Pharmaceuticals International, plc and Teleflex Incorporated · Updated 2026-09-07
KNSA currently screens as fairly valued while TFX screens as undervalued. Within Healthcare, TFX currently sits closer to the top of our discount ranking.
| KNSA | TFX | |
|---|---|---|
| Verdict | Fairly valued | Undervalued |
| Last price | $73.41 | $141.56 |
| 12-month range | $37.47–$73.41 | $103.36–$140.48 |
| Sector rank | #58 of 113 Healthcare | #56 of 113 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Low |
| Margin trend | — | Stable |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: KNSA fair value analysis · TFX fair value analysis